ヘパリンの世界市場:未分画ヘパリン、低分子量ヘパリン、超低分子量ヘパリン...市場調査レポートについてご紹介

【英文タイトル】Global Heparin Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Product Profiles
05.1.1 Arixtra
05.1.2 Fraxiparine
05.1.3 Innohep
05.1.4 Fragmin
05.1.5 Lovenox/Clexane

06.Introduction

07.Mechanism of Action
07.1 Mechanism of Action
07.2 Pharmacology of UFH
07.3 Pharmacology of LMWH

08.Clinical Uses of Heparin
08.1 DVT
08.2 Pulmonary Embolism
08.3 Acute Coronary Syndrome
08.4 Atrial Fibrillation
08.5 Hemodialysis
08.6 Coronary Angioplasty

09.Limitations of Heparin Use
09.1 Pharmacokinetic Limitations
09.2 Biophysical Limitations
09.3 Biological Limitations

10.Suppliers of Crude Heparin
10.1 FDA Guidance for Heparin Suppliers

11.Market Landscape
11.1 Market Overview
11.2 Market Size and Forecast
11.3 Five Forces Analysis

12.Market Segmentation by Product Type
12.1 UFH
12.2 LMWH
12.2.1 Deaminative Cleavage with Nitrous Acid or Organic Nitrite
12.2.2 Chemical or Enzymatic Beta Elimination
12.2.3 Oxidative Depolymerization
12.3 ULMWH

13.Market Segmentation by Route of Administration
13.1 IV Injection/Infusion
13.2 SC Injection

14.Geographical Segmentation
14.1 Global Heparin Market by Geographical Segmentation 2014-2019

15.Buying Criteria

16.Market Growth Drivers

17.Drivers and Their Impact

18.Market Challenges

19.Impact of Drivers and Challenges

20.Market Trends

21.Trends and Their Impact

22.Vendor Landscape
22.1 Competitive Scenario
22.1.1 Key News
22.1.2 Mergers and Acquisitions
22.2 Market Share Research 2014
22.2.1 Sanofi
22.2.2 Pfizer
22.2.3 Aspen Pharma
22.2.4 LEO Pharma
22.3 Other and Future Prominent Vendors

23.Key Takeaways of Global Heparin Market

24.Key Vendor Research
24.1 Aspen
24.1.1 Key Facts
24.1.2 Business Overview
24.1.3 Business Segmentation by Revenue 2014
24.1.4 Geographical Segmentation by Revenue 2014
24.1.5 Business Strategy
24.1.6 Recent Developments
24.1.7 SWOT Analysis
24.2 LEO Pharma
24.2.1 Key Facts
24.2.2 Business Description
24.2.3 Business Segmentation
24.2.4 Revenue Comparison by Business Segmentation 2011-2013
24.2.5 Revenue by Geographical Segmentation
24.2.6 Business Strategy
24.2.7 Key Developments
24.2.8 SWOT Analysis
24.3 Pfizer
24.3.1 Key Facts
24.3.2 Business Overview
24.3.3 Business Segmentation by Revenue 2014
24.3.4 Business Segmentation by Revenue 2013 and 2014
24.3.5 Geographical Segmentation by Revenue 2014
24.3.6 Business Strategy
24.3.7 Key Developments
24.3.8 SWOT Analysis
24.4 Sanofi
24.4.1 Key Facts
24.4.2 Business Description
24.4.3 Business Segmentation
24.4.4 Revenue by Business Segmentation
24.4.5 Revenue Comparison 2012 and 2013
24.4.6 Sales by Geography
24.4.7 Business Strategy
24.4.8 Key Developments
24.4.9 SWOT Analysis

25.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Process of Blood Coagulation
Exhibit 3: Mechanism of Action
Exhibit 4: Process of Crude Heparin Production in China
Exhibit 5: Global Heparin Market 2014-2019 ($ billions)
Exhibit 6: Segmentation of Global Heparin Market by Product Type
Exhibit 7: Segmentation of Global Heparin Market by Route of Administration
Exhibit 8: Segmentation of Global Heparin Market by Geography 2014
Exhibit 9: Global Heparin Market Share 2014
Exhibit 10: Lovenox: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 11: Lovenox: Region-Wise Revenue Comparison 2010-2014 ($ millions)
Exhibit 12: Fragmin: YoY Growth Rate and Revenue 2010-2014 ($ millions)
Exhibit 13: Fragmin: Region-Wise Revenue Comparison 2012-2013 ($ millions)
Exhibit 14: Arixtra: YoY Growth Rate and Revenue of 2010-2013 ($ millions)
Exhibit 15: Arixtra: Region-Wise Revenue Comparison 2010-2013 ($ millions)
Exhibit 16: Fraxiparine: YoY Growth Rate and Revenue 2010-2013 ($ millions)
Exhibit 17: Fraxiparine: Region-Wise Revenue Comparison 2010-2013 ($ millions)
Exhibit 18: Key Takeaways of Heparin Market
Exhibit 19: Aspen: Business Segmentation by Revenue 2014 ($ millions)
Exhibit 20: Aspen: Geographical Segmentation by Revenue 2014
Exhibit 21: LEO Pharma: Business Segmentation
Exhibit 22: LEO Pharma: Revenue Comparison by Business Segmentation 2011-2013 ($ billions)
Exhibit 23: LEO Pharma: Revenue by Geographical Segmentation 2013
Exhibit 24: Pfizer: Business Segmentation by Revenue 2014
Exhibit 25: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 26: Pfizer: Geographical Segmentation by Revenue 2014
Exhibit 27: Sanofi: Business Segmentation
Exhibit 28: Sanofi: Revenue by Business Segmentation 2013
Exhibit 29: Sanofi: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 30: Sanofi: Sales Revenue by Geographical Segmentation 2013


【レポート販売概要】

■ タイトル:ヘパリンの世界市場:未分画ヘパリン、低分子量ヘパリン、超低分子量ヘパリン
■ 英文:Global Heparin Market 2015-2019
■ 発行日:2015年6月10日
■ 調査会社:Technavio
■ 商品コード:IRTNTR6129
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。